{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:00:35Z","timestamp":1790938835522,"version":"4.1.0"},"reference-count":82,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Despite investors\u2019 pivotal role in shaping biomedical innovation, interaction between the investment community and health economics and outcomes research professionals remains limited. Both communities seek to understand what society values and how to allocate resources accordingly, yet these conversations occur largely in parallel. This perspective article, written from the viewpoint of a health economist who joined a major biomedical investment firm, seeks to bridge that divide. Drawing on first-hand observations across three domains \u2013 profits, incentives and societal value; coverage, pricing and patient access; and public policy and innovation \u2013 it argues that health economics and outcomes research must reconnect with its economic foundations, incorporate insights from real-world investment practice, and update its methods to better inform policy, promote innovation and improve patient welfare in a market-based system.<\/jats:p>","DOI":"10.57264\/cer-2026-0087","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:23:16Z","timestamp":1789474996000},"source":"Crossref","is-referenced-by-count":0,"title":["Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2797-3019","authenticated-orcid":false,"given":"Richard Z","family":"Xie","sequence":"first","affiliation":[{"name":"RA Capital Management, 200 Berkeley St, 18th Floor, Boston, MA 02116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","unstructured":"Pizzi LT Higashi MK. ISPOR 2026\u20132027 Top 10 HEOR Trends. ISPOR\u2014The Professional Society for Health Economics and Outcomes Research (2026). https:\/\/www.ispor.org\/heor-resources\/top-10-heor-trends"},{"key":"e_1_3_8_4_2","unstructured":"ISPOR. HEOR meets investing\u2014why are banks and VCs collaborating with health economists? ISPOR Webinar (2December 2025). https:\/\/www.ispor.org\/conferences-education\/event\/2025\/12\/02\/default-calendar\/heor-meets-investing-why-are-banks-and-vcs-collaborating-with-health-economists"},{"issue":"2","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jval.2016.12.005","article-title":"Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis","volume":"20","author":"Garrison LP","year":"2017","unstructured":"Garrison LP, Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health 20(2), 213\u2013216 (2017).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"e240213","DOI":"10.57264\/cer-2024-0213","article-title":"Generalized cost-effectiveness analysis: charting a path forward for measuring the societal value of medical technologies","volume":"14","author":"Li M","year":"2024","unstructured":"Li M. Generalized cost-effectiveness analysis: charting a path forward for measuring the societal value of medical technologies. J. Comp. Eff. Res. 14(1), e240213 (2024).","journal-title":"J. Comp. Eff. Res."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1515\/fhep-2024-0014","article-title":"Valuing the societal impact of medicines and other health technologies: a user guide to current best practices","volume":"27","author":"Shafrin J","year":"2024","unstructured":"Shafrin J, Kim J, Cohen JT Valuing the societal impact of medicines and other health technologies: a user guide to current best practices. Forum Health Econ. Policy 27(1), 29\u2013116 (2024).","journal-title":"Forum Health Econ. Policy"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01036-3"},{"issue":"3","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s43441-025-00768-0","article-title":"The impact of the Inflation Reduction Act on investment in innovative medicines: a project-level analysis","volume":"59","author":"Xie RZ","year":"2025","unstructured":"Xie RZ, Cameron T, Kolchinsky P. The impact of the Inflation Reduction Act on investment in innovative medicines: a project-level analysis. Ther. Innov. Regul. Sci. 59(3), 409\u2013417 (2025).","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"11","key":"e_1_3_8_10_2","first-page":"qxaf200","article-title":"Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?","volume":"3","author":"Hofer MP","year":"2025","unstructured":"Hofer MP, Radu P, Berdud M Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights? Health Aff. Sch. 3(11), qxaf200 (2025).","journal-title":"Health Aff. Sch."},{"issue":"9","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.respol.2011.05.021","article-title":"US biopharmaceutical finance and the sustainability of the biotech business model","volume":"40","author":"Lazonick W","year":"2011","unstructured":"Lazonick W, Tulum \u00d6. US biopharmaceutical finance and the sustainability of the biotech business model. Res. Policy 40(9), 1170\u20131187 (2011).","journal-title":"Res. Policy"},{"issue":"12","key":"e_1_3_8_12_2","first-page":"qxae129","article-title":"Evidence to inform biopharmaceutical policy: call for research on the impact of public policies on investment in drug development","volume":"2","author":"Barbosu S","year":"2024","unstructured":"Barbosu S, Axelsen K, Ezell S. Evidence to inform biopharmaceutical policy: call for research on the impact of public policies on investment in drug development. Health Aff. Sch. 2(12), qxae129 (2024).","journal-title":"Health Aff. Sch."},{"key":"e_1_3_8_13_2","unstructured":"Axelsen K Barbosu S. The relationship between biopharma R&D investment and expected returns: improving evidence to inform policy. ITIF Report (2024). https:\/\/itif.org\/publications\/2024\/05\/06\/relationship-between-biopharma-rd-investment-expected-returns\/"},{"issue":"3","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jfineco.2022.12.004","article-title":"Common ownership and innovation efficiency","volume":"147","author":"Li X","year":"2023","unstructured":"Li X, Liu T, Taylor LA. Common ownership and innovation efficiency. J. Financ. Econ. 147(3), 475\u2013497 (2023).","journal-title":"J. Financ. Econ."},{"key":"e_1_3_8_15_2","article-title":"US Venture Capital Index and Selected Benchmark Statistics","author":"Cambridge Associates","year":"2018","unstructured":"Cambridge Associates. US Venture Capital Index and Selected Benchmark Statistics. Cambridge Associates Report (2018). https:\/\/www.cambridgeassociates.com\/wp-content\/uploads\/2018\/10\/WEB-2018-Q2-USVC-Benchmark-Book.pdf","journal-title":"Cambridge Associates Report"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0105"},{"issue":"9","key":"e_1_3_8_17_2","first-page":"1546","article-title":"Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990\u20132015","volume":"39","author":"Buxbaum JD","year":"2020","unstructured":"Buxbaum JD, Chernew ME, Fendrick AM, Cutler DM. Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990\u20132015. Health Aff. 39(9), 1546\u20131556 (2020).","journal-title":"Health Aff."},{"key":"e_1_3_8_18_2","unstructured":"Goldman D Lakdawalla D. The global burden of medical innovation. USC Schaeffer Center Whitepaper (2018). https:\/\/schaeffer.usc.edu\/research\/global-burden-of-medical-innovation\/"},{"key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi JA","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20\u201333 (2016).","journal-title":"J. Health Econ."},{"issue":"9","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018","volume":"323","author":"Wouters OJ","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA 323(9), 844\u2013853 (2020).","journal-title":"JAMA"},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41591-024-03218-w","article-title":"Advancing global antibiotic research, development and access","volume":"30","author":"Piddock LJV","year":"2024","unstructured":"Piddock LJV, Alimi Y, Anderson J Advancing global antibiotic research, development and access. Nat. Med. 30, 2432\u20132443 (2024).","journal-title":"Nat. Med."},{"key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s44259-025-00123-1","article-title":"Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria","volume":"3","author":"Rahman M","year":"2025","unstructured":"Rahman M, Gargate N, Laws M. Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria. npj Antimicrob. Resist. 3, 50 (2025).","journal-title":"npj Antimicrob. Resist."},{"issue":"2","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422002-00002","article-title":"The economics of follow-on drug research and development: trends in entry rates and the timing of development","volume":"22","author":"DiMasi JA","year":"2004","unstructured":"DiMasi JA, Paquette C. The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics 22(Suppl. 2), 1\u201314 (2004).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrd3296","article-title":"Competitiveness in follow-on drug R&D: a race or imitation?","volume":"10","author":"DiMasi JA","year":"2011","unstructured":"DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nat. Rev. Drug Discov. 10, 23\u201327 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rfs\/hhab024","article-title":"Missing novelty in drug development","volume":"35","author":"Krieger J","year":"2022","unstructured":"Krieger J, Li D, Papanikolaou D. Missing novelty in drug development. Rev. Financ. Stud. 35(2), 636\u2013679 (2022).","journal-title":"Rev. Financ. Stud."},{"issue":"15","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon CP","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495\u20131504 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195\u20132207 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: from discovery to cure","volume":"19","author":"Manns MP","year":"2022","unstructured":"Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 19(8), 533\u2013550 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.37765\/ajmc.2023.89468","article-title":"Generalized cost-effectiveness analysis to assess treatment value in hepatitis C","volume":"29","author":"Chou JW","year":"2023","unstructured":"Chou JW, Graf M, D\u00edaz Espinosa O, Brewer I, Heim Z, Baumgardner J. Generalized cost-effectiveness analysis to assess treatment value in hepatitis C. Am. J. Manag. Care 29(12), 696\u2013703 (2023).","journal-title":"Am. J. Manag. Care"},{"issue":"8","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jval.2024.04.011","article-title":"Estimating the allocation of the economic value generated by utilization of all-oral direct-acting antivirals for hepatitis C in the United States, 2015 to 2019","volume":"27","author":"Garrison LP","year":"2024","unstructured":"Garrison LP, Jiao B, Elsisi Z Estimating the allocation of the economic value generated by utilization of all-oral direct-acting antivirals for hepatitis C in the United States, 2015 to 2019. Value Health 27(8), 1021\u20131029 (2024).","journal-title":"Value Health"},{"issue":"583","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/ecoj.12199","article-title":"Knowledge spillovers, innovation and growth","volume":"125","author":"Aghion P","year":"2015","unstructured":"Aghion P, Jaravel X. Knowledge spillovers, innovation and growth. Econ. J. 125(583), 533\u2013573 (2015).","journal-title":"Econ. J."},{"key":"e_1_3_8_32_2","unstructured":"BioPharma Dive. German Merck's MS drug falls short in pair of Phase III tests. BioPharma Dive (December 2023). https:\/\/www.biopharmadive.com\/news\/merck-kgaa-evobrutinib-btk-multiple-sclerosis-negative-trial-results\/701706\/"},{"key":"e_1_3_8_33_2","unstructured":"Sanofi. Tolebrutinib GEMINI 1 and 2 Phase III study results in relapsing multiple sclerosis. Press release (20 September 2024). https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-09-20-09-30-00-2949552"},{"key":"e_1_3_8_34_2","article-title":"Roche's fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis","volume":"10","author":"Roche","year":"2025","unstructured":"Roche. Roche's fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis. Press release (November) 10 (2025). https:\/\/www.roche.com\/media\/releases\/med-cor-2025-11-10","journal-title":"Press release (November)"},{"issue":"1","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1080\/13696998.2021.1952795","article-title":"Continuing trends in US brand-name and generic drug competition","volume":"24","author":"Grabowski H","year":"2021","unstructured":"Grabowski H, Long G, Mortimer R, Bilginsoy M. Continuing trends in US brand-name and generic drug competition. J. Med. Econ. 24(1), 908\u2013917 (2021).","journal-title":"J. Med. Econ."},{"key":"#cr-split#-e_1_3_8_36_2.1","doi-asserted-by":"crossref","unstructured":"Mulcahy AW Schwam D Lovejoy SL. Rand Health Q. International Prescription Drug Price Comparisons: Estimates Using 2022 Data. 3(11) PMID: 38855386","DOI":"10.7249\/rhq-11-03-05"},{"key":"#cr-split#-e_1_3_8_36_2.2","unstructured":"Mulcahy AW Schwam D Lovejoy SL. Rand Health Q. International Prescription Drug Price Comparisons: Estimates Using 2022 Data. 3"},{"key":"#cr-split#-e_1_3_8_36_2.3","unstructured":"(11) PMID: 38855386; PMCID: PMC11147645 (2024)."},{"issue":"2","key":"e_1_3_8_37_2","first-page":"e44","article-title":"Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in Medicaid: economic model update","volume":"28","author":"Chhatwal J","year":"2022","unstructured":"Chhatwal J, Samur S, Kues B Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in Medicaid: economic model update. Am. J. Manag. Care 28(2), e44\u2013e52 (2022).","journal-title":"Am. J. Manag. Care"},{"issue":"6","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jval.2025.03.008","article-title":"US drug pricing patterns before loss of exclusivity","volume":"28","author":"Lin CH","year":"2025","unstructured":"Lin CH, Campbell JD, Motyka J, Cohen JT. US drug pricing patterns before loss of exclusivity. Value Health 28(6), 907\u2013914 (2025).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1017\/S0266462322000150","article-title":"Should we pay for scientific knowledge spillovers? The underappreciated value of \u201cfailed\u201d R&D efforts","volume":"38","author":"Xie RZ","year":"2022","unstructured":"Xie RZ, Towse A, Garrison LP. Should we pay for scientific knowledge spillovers? The underappreciated value of \u201cfailed\u201d R&D efforts. Int. J. Technol. Assess. Health Care 38(1), e31 (2022).","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"9","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1287\/mnsc.2020.3775","article-title":"Trials and terminations: learning from competitors' R&D failures","volume":"67","author":"Krieger JL","year":"2021","unstructured":"Krieger JL. Trials and terminations: learning from competitors' R&D failures. Manage. Sci. 67(9), 5525\u20135548 (2021).","journal-title":"Manage. Sci."},{"key":"e_1_3_8_41_2","unstructured":"Goldman D Grogan J Lakdawalla D Mitigating the Inflation Reduction Act's adverse impacts on the prescription drug market. USC Schaeffer Center Whitepaper (2023). https:\/\/schaeffer.usc.edu\/research\/mitigating-the-inflation-reduction-acts-potential-adverse-impacts-on-the-prescription-drug-market\/"},{"issue":"8","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim AS","year":"2016","unstructured":"Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 316(8), 858\u2013871 (2016).","journal-title":"JAMA"},{"key":"e_1_3_8_43_2","unstructured":"Sood N Shih T Van Nuys K Flow of money through the pharmaceutical distribution system. USC Schaeffer Center Whitepaper (2017). https:\/\/schaeffer.usc.edu\/research\/flow-of-money-through-the-pharmaceutical-distribution-system\/"},{"issue":"1","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jval.2021.06.014","article-title":"Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications","volume":"25","author":"Neumann PJ","year":"2022","unstructured":"Neumann PJ, Podolsky MI, Basu A Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications. Value Health 25(1), 59\u201368 (2022).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40258-024-00928-7","article-title":"Estimating a drug's price after loss of exclusivity as a function of its cost of goods sold","volume":"23","author":"Whittington MD","year":"2025","unstructured":"Whittington MD, Mattingly TJ. Estimating a drug's price after loss of exclusivity as a function of its cost of goods sold. Appl. Health Econ. Health Policy 23(1), 75\u201383 (2025).","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"9","key":"e_1_3_8_46_2","first-page":"qxaf169","article-title":"How time is accounted for when modeling pharmaceutical impacts: investment vs. assessment perspectives","volume":"3","author":"Whittington MD","year":"2025","unstructured":"Whittington MD, Garrison LP, O'Brien JM, Campbell JD. How time is accounted for when modeling pharmaceutical impacts: investment vs. assessment perspectives. Health Aff. Sch. 3(9), qxaf169 (2025).","journal-title":"Health Aff. Sch."},{"issue":"10","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders GD","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316(10), 1093\u20131103 (2016).","journal-title":"JAMA"},{"key":"e_1_3_8_48_2","unstructured":"Feuerstein A. At $2.1 million newly approved Novartis gene therapy will be world's most expensive drug. STAT News (24 May 2019). https:\/\/www.statnews.com\/2019\/05\/24\/hold-novartis-zolgensma-approval\/"},{"issue":"6","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"e2318145","DOI":"10.1001\/jamanetworkopen.2023.18145","article-title":"Assessment of commercial and mandatory discounts in the gross-to-net bubble for the top insulin products from 2012 to 2019","volume":"6","author":"Dickson SR","year":"2023","unstructured":"Dickson SR, Gabriel N, Gellad WF, Hernandez I. Assessment of commercial and mandatory discounts in the gross-to-net bubble for the top insulin products from 2012 to 2019. JAMA Netw. Open 6(6), e2318145 (2023).","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"lsac022","DOI":"10.1093\/jlb\/lsac022","article-title":"Biological patent thickets and delayed access to biosimilars, an American problem","volume":"9","author":"Lidow N","year":"2022","unstructured":"Lidow N, Kesselheim AS, Rome BN. Biological patent thickets and delayed access to biosimilars, an American problem. J. Law Biosci. 9(2), lsac022 (2022).","journal-title":"J. Law Biosci."},{"issue":"1","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1177\/0033354920904608","article-title":"Enforcement of legal remedies to secure hepatitis C virus treatment with direct-acting antiviral therapies in correctional facilities and Medicaid programs","volume":"135","author":"Greenwald R","year":"2020","unstructured":"Greenwald R, Waters P, Cayer S. Enforcement of legal remedies to secure hepatitis C virus treatment with direct-acting antiviral therapies in correctional facilities and Medicaid programs. Public Health Rep. 135(Suppl. 1), S44\u2013S49 (2020).","journal-title":"Public Health Rep."},{"issue":"12","key":"e_1_3_8_52_2","first-page":"1319","article-title":"Understanding payer perspectives on value in the use of pharmaceuticals in the United States","volume":"25","author":"Brogan AP","year":"2019","unstructured":"Brogan AP, Hogue SL, Vekaria RM, Reynolds I, Coukell A. Understanding payer perspectives on value in the use of pharmaceuticals in the United States. J. Manag. Care Spec. Pharm. 25(12), 1319\u20131327 (2019).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"3","key":"e_1_3_8_53_2","first-page":"257","article-title":"Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions","volume":"29","author":"Chambers JD","year":"2023","unstructured":"Chambers JD, Enright DE, Panzer AD, Cohen JT, Ollendorf DA, Neumann PJ. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions. J. Manag. Care Spec. Pharm. 29(3), 257\u2013264 (2023).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"2","key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force Report","volume":"21","author":"Lakdawalla DN","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force Report. Value Health 21(2), 131\u2013139 (2018).","journal-title":"Value Health"},{"key":"e_1_3_8_55_2","unstructured":"Cystic Fibrosis South Australia. A tough pill to swallow\u2026access deferred. https:\/\/www.cfsa.org.au\/trikafta-access-deferred\/"},{"issue":"19","key":"e_1_3_8_56_2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton PG","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381(19), 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_57_2","unstructured":"Vertex Pharmaceuticals. Vertex announces reimbursement agreement in Australia for TRIKAFTA\u00ae for patients with cystic fibrosis. Press release (27 March 2022). https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-reimbursement-agreement-australia-trikaftar"},{"key":"e_1_3_8_58_2","doi-asserted-by":"crossref","unstructured":"Mulcahy AW. Rand Health Q. Comparing New Prescription Drug Availability and Launch Timing in the United States and Other OECD Countries. 3(11) PMID: 38855389; PMCID: PMC11147638 (2024).","DOI":"10.7249\/rhq-11-03-04"},{"issue":"2","key":"e_1_3_8_59_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla DN","year":"2021","unstructured":"Lakdawalla DN, Phelps CE. Health technology assessment with diminishing returns to health: the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) approach. Value Health 24(2), 244\u2013249 (2021).","journal-title":"Value Health"},{"key":"e_1_3_8_60_2","unstructured":"Lakdawalla D Phelps CE Arndorfer S Getting the math right when measuring the value of new medicines. EntityRisk White Paper (2023). https:\/\/nopatientleftbehind.docsend.com\/view\/889u6zs74tra9x4a"},{"key":"e_1_3_8_61_2","unstructured":"Fattah M Miller S. Anthem Blue Cross Blue Shield halts anesthesia payment policy after backlash. NBC News (5 December 2024). https:\/\/www.nbcnews.com\/health\/health-care\/anthem-blue-cross-blue-shield-time-limits-anesthesia-surgery-rcna183035"},{"key":"e_1_3_8_62_2","unstructured":"Pestaina K Pollitz K Rae M. Claims denials and appeals in ACA marketplace plans 2021. KFF Issue Brief (January 2023). https:\/\/www.kff.org\/private-insurance\/issue-brief\/claims-denials-and-appeals-in-aca-marketplace-plans\/"},{"key":"e_1_3_8_63_2","unstructured":"Kolchinsky P Tadvalkar L Xie R. How GCEA stopped us from sandbagging our pricing and peak sales estimates for Cidara's flu drug. RApport (20 August 2025). https:\/\/www.racap.com\/rapport\/cidara-gcea-flu-drug"},{"key":"e_1_3_8_64_2","unstructured":"Merck. Merck to acquire Cidara Therapeutics Inc. diversifying its portfolio to include late-phase antiviral agent. Press release (14 November 2025). https:\/\/www.merck.com\/news\/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent\/"},{"issue":"20","key":"e_1_3_8_65_2","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.285.20.2622","article-title":"The end of managed care","volume":"285","author":"Robinson JC","year":"2001","unstructured":"Robinson JC. The end of managed care. JAMA 285(20), 2622\u20132628 (2001).","journal-title":"JAMA"},{"issue":"5","key":"e_1_3_8_66_2","first-page":"941","article-title":"Uncertainty and the welfare economics of medical care","volume":"53","author":"Arrow KJ","year":"1963","unstructured":"Arrow KJ. Uncertainty and the welfare economics of medical care. Am. Econ. Rev. 53(5), 941\u2013973 (1963).","journal-title":"Am. Econ. Rev."},{"issue":"3","key":"e_1_3_8_67_2","first-page":"531","article-title":"The economics of moral hazard: comment","volume":"58","author":"Pauly MV","year":"1968","unstructured":"Pauly MV. The economics of moral hazard: comment. Am. Econ. Rev. 58(3), 531\u2013537 (1968).","journal-title":"Am. Econ. Rev."},{"issue":"3","key":"e_1_3_8_68_2","first-page":"251","article-title":"Health insurance and the demand for medical care: evidence from a randomized experiment","volume":"77","author":"Manning WG","year":"1987","unstructured":"Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am. Econ. Rev. 77(3), 251\u2013277 (1987).","journal-title":"Am. Econ. Rev."},{"issue":"1","key":"e_1_3_8_69_2","first-page":"4","article-title":"Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: a systematic literature review","volume":"29","author":"Fusco N","year":"2023","unstructured":"Fusco N, Sils B, Graff JS, Kistler K, Ruiz K. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: a systematic literature review. J. Manag. Care Spec. Pharm. 29(1), 4\u201316 (2023).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"11","key":"e_1_3_8_70_2","doi-asserted-by":"crossref","first-page":"e213409","DOI":"10.1001\/jamahealthforum.2021.3409","article-title":"Estimation of the share of net expenditures on insulin captured by US manufacturers, wholesalers, pharmacy benefit managers, pharmacies, and health plans from 2014 to 2018","volume":"2","author":"Van Nuys K","year":"2021","unstructured":"Van Nuys K, Ribero R, Ryan M, Sood N. Estimation of the share of net expenditures on insulin captured by US manufacturers, wholesalers, pharmacy benefit managers, pharmacies, and health plans from 2014 to 2018. JAMA Health Forum. 2(11), e213409 (2021).","journal-title":"JAMA Health Forum."},{"issue":"9","key":"e_1_3_8_71_2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1377\/hlthaff.2023.01344","article-title":"Consumer out-of-pocket drug prices grew faster than prices faced by insurers after accounting for rebates, 2007\u201320","volume":"43","author":"Mallatt J","year":"2024","unstructured":"Mallatt J, Dunn A, Fernando L. Consumer out-of-pocket drug prices grew faster than prices faced by insurers after accounting for rebates, 2007\u201320. Health Aff. 43(9), 1284\u20131289 (2024).","journal-title":"Health Aff."},{"issue":"1","key":"e_1_3_8_72_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-024-03262-w","article-title":"Is the price right? Paying for value today to get more value tomorrow","volume":"22","author":"Ramagopalan SV","year":"2024","unstructured":"Ramagopalan SV, Diaz J, Mitchell G, Garrison LP Jr, Kolchinsky P. Is the price right? Paying for value today to get more value tomorrow. BMC Med. 22(1), 45 (2024).","journal-title":"BMC Med."},{"key":"e_1_3_8_73_2","unstructured":"IQVIA Institute. U.S. medicine use trends 2026. IQVIA (2026). https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/us-medicine-use-trends-2026"},{"key":"e_1_3_8_74_2","unstructured":"Centers for Medicare & Medicaid Services. National health expenditures 2024 highlights. CMS Office of the Actuary (2026). https:\/\/cms.gov\/files\/document\/nhe-infographic.pdf"},{"key":"e_1_3_8_75_2","unstructured":"Kolchinsky P. A lot for a little: the best 8% slice of our healthcare dollar. RApport (2024). https:\/\/rapport.racap.com\/all-stories\/best-8-percent-of-our-healthcare-dollar"},{"issue":"10","key":"e_1_3_8_76_2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1377\/hlthaff.2024.00202","article-title":"Postapproval innovation for oncology drugs and the Inflation Reduction Act","volume":"43","author":"Grabowski H","year":"2024","unstructured":"Grabowski H, DiMasi JA, Long G. Postapproval innovation for oncology drugs and the Inflation Reduction Act. Health Aff. 43(10), 1400\u20131409 (2024).","journal-title":"Health Aff."},{"issue":"4","key":"e_1_3_8_77_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s43441-025-00774-2","article-title":"The Inflation Reduction Act and drug development: potential early signals of impact on post-approval clinical trials","volume":"59","author":"Zheng H","year":"2025","unstructured":"Zheng H, Patterson JA, Campbell JD. The Inflation Reduction Act and drug development: potential early signals of impact on post-approval clinical trials. Ther. Innov. Regul. Sci. 59(4), 781\u2013789 (2025).","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"12","key":"e_1_3_8_78_2","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1016\/j.jval.2024.10.1596","article-title":"Estimating the impacts of government-mandated price reductions on indication expansion for launched drugs: a real-world study","volume":"27","author":"Rhuda J","year":"2024","unstructured":"Rhuda J, Xie R, Cameron T, Kolchinsky P. Estimating the impacts of government-mandated price reductions on indication expansion for launched drugs: a real-world study. Value Health 27(12), S308 (2024).","journal-title":"Value Health"},{"key":"e_1_3_8_79_2","article-title":"Import price, import threshold: how foreign reference pricing embeds valuations and risks undermining global innovation","author":"Shafrin J","unstructured":"Shafrin J, Garrison LP, Xie RZ. Import price, import threshold: how foreign reference pricing embeds valuations and risks undermining global innovation. Health Aff. Forefront (24 June 2026). https:\/\/www.healthaffairs.org\/content\/forefront\/import-price-import-threshold-foreign-reference-pricing-embeds-valuations-and-risks","journal-title":"Health Aff."},{"key":"e_1_3_8_80_2","unstructured":"Kolchinsky P Xie R. No more freeriding on the Great American Drug Deal. RApport (2025). https:\/\/rapport.racap.com\/all-stories\/no-more-freeriding-great-american-drug-deal"},{"issue":"8","key":"e_1_3_8_81_2","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hec.70105","article-title":"Pharmaceutical pricing and R&D as a global public good","volume":"35","author":"Frech HE","year":"2026","unstructured":"Frech HE III, Pauly MV, Comanor WS, Martinez JR. Pharmaceutical pricing and R&D as a global public good. Health Econ. 35(8), 1158\u20131174 (2026).","journal-title":"Health Econ."},{"key":"e_1_3_8_82_2","unstructured":"Office of the United States Trade Representative. US Government announces agreement in principle with the United Kingdom on pharmaceutical pricing. Press release (1 December 2025). https:\/\/ustr.gov\/about\/policy-offices\/press-office\/press-releases\/2025\/december\/us-government-announces-agreement-principle-united-kingdom-pharmaceutical-pricing"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:43:15Z","timestamp":1790937795000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.57264\/cer-2026-0087"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0087","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"e260087"}}